Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences; National and Local United Engineering Lab of Druggability and New Drugs Evaluation, Sun Yat-Sen University, Guangzhou 510006, China.
Aab Cardiovascular Research Institute, University of Rochester School of Medicine and Dentistry, Rochester, New York, 14642, USA.
Acta Pharmacol Sin. 2018 May;39(5):802-824. doi: 10.1038/aps.2017.193. Epub 2018 Apr 26.
Salvia miltiorrhiza Burge (Danshen) is an eminent medicinal herb that possesses broad cardiovascular and cerebrovascular protective actions and has been used in Asian countries for many centuries. Accumulating evidence suggests that Danshen and its components prevent vascular diseases, in particular, atherosclerosis and cardiac diseases, including myocardial infarction, myocardial ischemia/reperfusion injury, arrhythmia, cardiac hypertrophy and cardiac fibrosis. The published literature indicates that lipophilic constituents (tanshinone I, tanshinone IIa, tanshinone IIb, cryptotanshinone, dihydrotanshinone, etc) as well as hydrophilic constituents (danshensu, salvianolic acid A and B, protocatechuic aldehyde, etc) contribute to the cardiovascular protective actions of Danshen, suggesting a potential synergism among these constituents. Herein, we provide a systematic up-to-date review on the cardiovascular actions and therapeutic potential of major pharmacologically active constituents of Danshen. These bioactive compounds will serve as excellent drug candidates in small-molecule cardiovascular drug discovery. This article also provides a scientific rationale for understanding the traditional use of Danshen in cardiovascular therapeutics.
丹参(Salvia miltiorrhiza Burge)是一种著名的药用植物,具有广泛的心血管和脑血管保护作用,在亚洲国家已使用了数个世纪。越来越多的证据表明,丹参及其成分可预防血管疾病,特别是动脉粥样硬化和心脏病,包括心肌梗死、心肌缺血/再灌注损伤、心律失常、心肌肥厚和心肌纤维化。已发表的文献表明,脂溶性成分(丹参酮 I、丹参酮 IIa、丹参酮 IIb、隐丹参酮、二氢丹参酮等)和水溶性成分(丹参素、丹酚酸 A 和 B、原儿茶醛等)都有助于丹参的心血管保护作用,这表明这些成分之间可能存在协同作用。在此,我们对丹参中主要的具有药理活性的成分的心血管作用和治疗潜力进行了系统的最新综述。这些生物活性化合物将作为小分子心血管药物发现的优秀候选药物。本文还为理解丹参在心血管治疗中的传统应用提供了科学依据。